Banca de DEFESA: Vitória Tavares de Castro

Uma banca de DEFESA de MESTRADO foi cadastrada pelo programa.
STUDENT : Vitória Tavares de Castro
DATE: 02/03/2023
TIME: 14:30
LOCAL: Plataforma Teams
TITLE:

Detection of anti-SARS-CoV-2 salivary antibodies in vaccinated adults.

KEY WORDS:

COVID-19; SARS-CoV-2, saliva, antibodies, neutralizing antibodies, IgG, IgA, COVID-19 vaccines

PAGES: 100
BIG AREA: Ciências da Saúde
AREA: Odontologia
SUMMARY:

The present work was proposed to evaluate the viability of saliva as an alternative for detecting anti-SARS-CoV-2 antibodies. This work was divided into 2 studies. The first aims to evaluate the detection of anti-SARS-CoV-2 antibodies in saliva after vaccination using the rapid systematic review methodology. Fifteen studies were included, with approximately 1,080 saliva samples from vaccinated and/or convalescent individuals. Vaccines were mainly RNA-based, including recombinant viral vector vaccines as well. The techniques applied for the evaluation of salivary antibodies included ELISA assay, Multiplex Immunoassay, Flow Cytometry, Neutralization and Electrochemical assays. IgG, but not IgA, was frequently presented in saliva from vaccinated antiCOVID-19. Although antibody titers are lower in saliva than in serum, the results showed that saliva is suitable for antibody detection. The second study was of the longitudinal experimental type and aimed to evaluate the detection of anti-SARS-CoV-2 antibodies in the serum and saliva of vaccinated adults. 13 participants were included as a negative control and 35 participants vaccinated with two doses of the CoronaVac vaccine who subsequently received the Pfizer vaccine as a third dose. Vaccinated participants were evaluated after the second dose, one month and five months after the third dose, totaling 118 saliva samples. The ELISA assay was used to detect neutralizing antibodies (NAb), IgA and IgG. Also, electrochemiluminescence for detection of total antibodies (TAb) in 20 initial samples. TAb was detected in 10/10 samples in serum (158.13±88.1 U/mL) and only in 3/10 in saliva (0.63±0.46 U/mL) after the second dose. In serum, NAb was detected in 34/35 participants after the second dose (57.86±20.74%) and in 35/35 participants one month (95.6±3.34%) and five months (95.03 ±1.17%) after the third dose (p<0.0001). In saliva, NAb was detected in 30/35 samples after the second dose (6.54±5.54%), and in 35/35 samples one month (29.51±11.96%) and five months (10. 17±4.99%) after the third dose (p<0.0001). IgA was detected in 19/34 saliva samples after the second dose (1.46±1.01 ratio), 18/35 saliva samples one month after the third dose (1.71±1.65 ratio) and 30/35 five months after the third dose (2.69 ±1.72 ratio) (p<0.0013). IgG was detected in 1/34 saliva samples after the second dose (0.38±0.21 ratio), 33/35 saliva samples one month after the third dose (3.08±1.63 ratio) and 20 /35 saliva samples five months after the third dose (1.44±0.76 rare) (p<0.0001). There was a positive correlation between NAb and TAb in serum (r=0.6634), NAb in serum and IgG in saliva (r=0.7896), and NAb and IgG both in saliva (r=0.6115). Excellent sensitivity was observed for the salivary NAb test (95%). The salivary IgG test showed excellent sensitivity (100%) overall, excellent accuracy (100%) one month after the third dose, and still good accuracy (85%) five months after the third dose. NAb, IgA and IgG antibodies were found in the vaccinated saliva. In conclusion, studies have shown that anti-SARS-CoV-2 antibodies can be found in the saliva of individuals vaccinated for COVID-19.

BANKING MEMBERS:
Externa à Instituição - NÁDIA DO LAGO COSTA - UFG
Interna - 2295825 - ANA CAROLINA ACEVEDO POPPE
Presidente - 1278451 - ELIETE NEVES DA SILVA GUERRA
Externa ao Programa - 1562111 - PEROLA DE OLIVEIRA MAGALHAES DIAS BATISTA